Sienna Biopharmaceuticals Up In IPO

Westlake Village-based Sienna Biopharmaceuticals had its IPO this morning on the NASDAQ, and was up over 33 percent in morning trading on its first day trading as SNNA, trading at around $19.98. Sienna had priced its IPO on Wednesday night at $15.00 per share, selling 4,333,333 shares of its stock in its public offering. The aesthetic medicine developer, led by President and CEO Dr. Frederick C. Beddingfield III, is venture backed by ARCH Venture Partners, Partner Fund, and Fidelity. The IPO was managed by J.P. Morgan, Cowen, and BM Capital Markets.